

THE WHITE HOUSE WASHINGTON

COVID-19 Press Briefing

October 1, 2021



Daily Change in COVID-19 Cases, US

January 22, 2020 – September 29, 2021

300,000 TOTAL Cases Reported Since 1/22/20 250,000 43,289,203 LATEST AVERAGE* NEW Cases Reported to CDC on 9/29/21 200,000 106,395 New Cases 111,086 150,000 Change in 7-Day Case Average 100,000 -13.3% RECENT LOW AVERAGE* 50,000 Current 7-Day Case Average (9/23/21 - 9/29/21) 11,519 106,395 Apr 2020 Jul 2020 Oct 2020 Jan 2021 Apr 2021 Jul 2021 Prior 7-Day Case Average (9/16/21 - 9/22/21) **Date of Report** • Latest Average • Low Average • New Cases — 7-Day Moving Average - New Cases* 122,659 *7-day averages exclude historical cases reported retroactively by states



New Admissions of Patients with Confirmed COVID-19, US

August 1, 2020 – September 28, 2021

Patients Currently Hospitalized with COVID on 9/28/21

68,794

New Admissions on 9/28/21

8,415

Peak in New Admissions (1/5/21)


17,958

Change in 7-Day Average of New Admissions

```
-14.9%
```

```
Current 7-Day Average of New Admissions (9/22/21 - 9/28/21)
8,321
```

```
Prior 7-Day Average of New Admissions (9/15/21 - 9/21/21)
9,782
```



• Latest Average • Low Average • New Admissions — 7-Day Moving Average - New Admissions



Daily Change in COVID-19 Deaths, US

January 22, 2020 – September 29, 2021

TOTAL Deaths Reported Since 1/22/2020

694,701


NEW Deaths Reported to CDC on 9/29/21 2,008

Change in 7-Day Death Average

-3.3%


Current 7-Day Death Average (9/23/21 - 9/29/21) 1,476

Prior 7-Day Death Average (9/16/21 - 9/22/21) 1,527 Forecasted Total Deaths by 10/23/21 724,000 to 753,000





COVID-19-associated Cases, Hospitalizations, and Deaths in High, Medium, and Low Vaccine Coverage States



Accelerating the End of the COVID-19 Pandemic with Vaccination


- COVID-19 vaccines are safe, effective, convenient, and free; they protect you, your loved ones, and your community
- Booster shots provide further protection against SARS-CoV-2 infection and symptomatic COVID-19 disease and for people at increased risk of severe COVID-19 disease

Vaccines for children aged 5-11 years, pending FDA authorization and CDC recommendation, may soon be available to help protect our children and those around them





COVID-19 data over past 30 days



Source: https://kingcounty.gov/depts/health/covid-19/data/vaccination-outcomes.aspx



Accelerating the End of the COVID-19 Pandemic with Vaccination

- COVID-19 vaccines are safe, effective, convenient, and free; they protect you, your loved ones, and your community
- Booster shots provide further protection against SARS-CoV-2 infection and symptomatic COVID-19 disease and for people at increased risk of severe COVID-19 disease
- Vaccines for children aged 5-11 years, pending FDA authorization and CDC recommendation, may soon be available to help protect our children and those around them






Protection of BNT162b2 Vaccine Booster against Covid-19 in Israel

YM Bar-On, A Huppert et al.

- Data for period 7/30 8/31, 2021 from 1.14 million people aged 60 years and older who had received a 2nd dose of mRNA vaccine at least 5 months earlier
- 12 days or more after the booster dose, the rate of confirmed infection was lower in the booster group than in the non-booster group by a factor of 11.3; the rate of severe illness was lower by a factor of 19.5



Active Severe COVID-19 Cases by Vaccination Status, Age 60+ Years, Israel (per 100K Population) as of Sept. 28, 2021



Source: Israel MOH, https://datadashboard.health.gov.il



Accelerating the End of the COVID-19 Pandemic with Vaccination

- COVID-19 vaccines are safe, effective, convenient, and free; they protect you, your loved ones, and your community
- Booster shots provide further protection against SARS-CoV-2 infection and symptomatic COVID-19 disease and for people at increased risk of severe COVID-19 disease

Vaccines for children aged 5-11 years, pending FDA authorization and CDC recommendation, may soon be available to help protect our children and those around them



On Sept. 28, 2021, Pfizer and BioNTech submitted data to U.S. FDA from phase 2/3 trials of their COVID-19 vaccine (BNT162b2) in children 5 to 11 years of age

N=2,268

Companies report that the BNT162b2 vaccine demonstrated a favorable safety profile and elicited robust neutralizing antibody responses using a two-dose regimen of 10 µg doses





Find COVID-19 Vaccine Near You



Visit vaccines.gov

Text your ZIP code to 438829

Call 1-800-232-0233





THE WHITE HOUSE WASHINGTON

